サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720767

先天性副腎過形成の世界市場レポート 2025年

Congenital Adrenal Hyperplasia Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
先天性副腎過形成の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

先天性副腎過形成市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で6億6,000万米ドルに成長します。この予測期間における成長は、個別化医療に対する需要の高まり、遺伝性疾患の発生率の増加、先天性副腎過形成治療に関する調査の増加、ヘルスケア投資の増加、症状管理における遠隔医療の利用拡大などに起因しています。主な動向としては、ヘルスケアインフラの発展、分子診断学の進歩、酵素補充療法の開発、長時間作用型コルチコステロイド製剤の開発、遺伝子スクリーニングの改善などが挙げられます。

遺伝子治療に対する需要の高まりが、今後数年間の先天性副腎過形成市場の成長を牽引すると予想されます。遺伝子治療は、病気の治療や予防のために個人の遺伝子を修正・操作する医療技術です。遺伝子治療に対する需要の高まりは、遺伝子研究やバイオテクノロジーの進歩により、遺伝性疾患、がん、その他の慢性疾患に対するより正確で的を絞った治療が可能になったことが背景にあります。副腎ホルモン産生に影響を及ぼす遺伝子変異に起因する先天性副腎過形成（CAH）は、遺伝子治療の重要な分野であり、根本的な欠陥を修正し、正常なホルモン機能を回復させる標的遺伝子介入の機会を提供しています。例えば、2024年4月、米国を拠点とする専門家会員組織である米国遺伝子細胞治療学会（ASGCT）は、希少疾患を対象に開発中の遺伝子治療薬1,023件のうち、上位10件のうち8件が腫瘍疾患を対象としていると報告しました。さらに、2024年第2四半期には遺伝子治療の臨床試験が25％増加し、新たに76試験が開始されました。このような遺伝子治療に対する需要の高まりが、先天性副腎過形成市場の拡大に寄与しています。

先天性副腎過形成市場の主要企業は、コルチゾール産生を調整し副腎アンドロゲン過剰を抑制するCRF1受容体拮抗薬などの革新的治療法の開発に注力しています。CRF1受容体拮抗薬は、コルチコトロピン放出因子1（CRF1）受容体をブロックする薬剤で、身体のストレス反応を調整し、CAHなどの状態における副腎アンドロゲン過剰産生を抑制するのに役立ちます。例えば、2024年12月、米国のバイオ医薬品会社ニューロクライン・バイオサイエンシズ社は、70年ぶりに先天性副腎過形成の新しい治療薬であるクレネス（クリネカーフォント）のFDA承認を取得しました。この内服薬は、コルチコトロピン放出因子1型受容体の選択的拮抗薬として機能し、過剰な副腎皮質刺激ホルモン（ACTH）と副腎アンドロゲンの調節を助けると同時に、グルココルチコイドの低用量投与を可能にします。承認は、CAHtalystフェーズ3試験のデータに基づいており、アンドロゲンレベルを低下させる有意な有効性が示されました。Crenessityは間もなく発売される予定であり、CAH管理における大きな進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界先天性副腎過形成PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の先天性副腎過形成市場：成長率分析
  • 世界の先天性副腎過形成市場の実績：規模と成長, 2019-2024
  • 世界の先天性副腎過形成市場の予測：規模と成長, 2024-2029, 2034F
  • 世界先天性副腎過形成総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の先天性副腎過形成市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • クラシック先天性副腎過形成
  • 非クラシック先天性副腎過形成
  • 世界の先天性副腎過形成市場治療と診断によって、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 診断
  • 治療
  • 世界の先天性副腎過形成市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門クリニック
  • 外来手術センター
  • 調査機関
  • 世界の先天性副腎過形成市場、先天性副腎過形成症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 塩を無駄にする古典先天性副腎過形成
  • シンプルに男らしさを演出するクラシック先天性副腎過形成
  • 世界の先天性副腎過形成市場非典型的先天性副腎過形成症の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 晩発性非典型性先天性副腎過形成
  • マイルドな非クラシック先天性副腎過形成

第7章 地域別・国別分析

  • 世界の先天性副腎過形成市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の先天性副腎過形成市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 先天性副腎過形成市場：競合情勢
  • 先天性副腎過形成市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Eton Pharmaceuticals Inc
  • Teva Pharmaceutical Industries
  • Macleods Pharmaceuticals
  • H. Lundbeck A/S
  • Neurocrine Biosciences Inc.
  • BridgeBio Pharma Inc
  • Regenxbio Inc.
  • Millendo Therapeutics Inc.
  • Applied Therapeutics, Inc.
  • OMass Therapeutics Limited
  • ViennaLab Diagnostics GmbH
  • EffRx Pharmaceuticals SA
  • Adrenas Therapeutics Inc
  • HBM Alpha Therapeutics
  • Spruce Biosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 先天性副腎過形成市場2029：新たな機会を提供する国
  • 先天性副腎過形成市場2029：新たな機会を提供するセグメント
  • 先天性副腎過形成市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34023

Congenital adrenal hyperplasia (CAH) is a group of inherited disorders that impact adrenal gland function due to enzyme deficiencies, primarily 21-hydroxylase. Management involves hormone replacement therapy to regulate cortisol and aldosterone levels, suppress excess androgen production, and address symptoms such as electrolyte imbalances and abnormal physical development.

The main types of CAH are classic and non-classic congenital adrenal hyperplasia. Classic CAH is a genetic disorder mainly caused by 21-hydroxylase deficiency, resulting in cortisol deficiency, excess androgen production, and potential aldosterone loss. Diagnosis and treatment take place across various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The congenital adrenal hyperplasia market research report is one of a series of new reports from The Business Research Company that provides congenital adrenal hyperplasia market statistics, including the congenital adrenal hyperplasia industry global market size, regional shares, competitors with the congenital adrenal hyperplasia market share, detailed congenital adrenal hyperplasia market segments, market trends, and opportunities, and any further data you may need to thrive in the congenital adrenal hyperplasia industry. This congenital adrenal hyperplasia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The congenital adrenal hyperplasia market size has grown strongly in recent years. It will grow from $0.47 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be credited to the rising prevalence of congenital adrenal hyperplasia, increased adoption of corticosteroid therapies, growing healthcare expenditure, a heightened focus on pediatric care, and expanding government initiatives and reimbursement policies.

The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to $0.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be credited to the rising demand for personalized medicine, an increasing incidence of genetic disorders, growing research on congenital adrenal hyperplasia treatments, higher healthcare investments, and the expanding use of telemedicine in managing the condition. Key trends include advancements in healthcare infrastructure, progress in molecular diagnostics, the development of enzyme replacement therapies, the creation of long-acting corticosteroid formulations, and improvements in genetic screening.

The increasing demand for gene therapy is expected to drive the growth of the congenital adrenal hyperplasia market in the coming years. Gene therapy is a medical technique that involves modifying or manipulating an individual's genes to treat or prevent disease. The rising demand for gene therapy is fueled by advancements in genetic research and biotechnology, enabling more precise and targeted treatments for genetic disorders, cancers, and other chronic diseases. Congenital adrenal hyperplasia (CAH), which results from genetic mutations affecting adrenal hormone production, is a key area for gene therapy, offering opportunities for targeted genetic interventions to correct underlying defects and restore normal hormone function. For example, in April 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, reported that out of 1,023 gene therapies in development for rare diseases, eight of the top 10 targeted oncological conditions. Additionally, the second quarter of 2024 saw a 25% increase in gene therapy trials, with 76 new studies initiated. This growing demand for gene therapy is contributing to the expansion of the congenital adrenal hyperplasia market.

Leading companies in the congenital adrenal hyperplasia market are focusing on developing innovative treatments such as CRF1 receptor antagonists to regulate cortisol production and reduce adrenal androgen excess. CRF1 receptor antagonists are drugs that block the corticotropin-releasing factor 1 (CRF1) receptor, helping to regulate the body's stress response and control excessive adrenal androgen production in conditions such as CAH. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia in 70 years. This oral medication functions as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to regulate excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for lower glucocorticoid doses. Approval was based on data from the CAHtalyst Phase 3 studies, which demonstrated significant efficacy in reducing androgen levels. Crenessity is expected to be available soon, representing a major advancement in CAH management.

In November 2022, Neurocrine Biosciences, Inc. expanded its portfolio by acquiring Diurnal Group Limited for an undisclosed amount. This acquisition aims to strengthen Neurocrine's presence in hormone therapeutics, accelerate the development of Diurnal's products, and enhance its market position in the UK for chronic endocrine diseases. Diurnal Group Limited, a UK-based biotech company, specializes in developing and commercializing hormone therapeutics for the treatment of chronic endocrine disorders, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism.

Major players in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., and Crinetics Pharmaceuticals Inc.

North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in congenital adrenal hyperplasia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the congenital adrenal hyperplasia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital adrenal hyperplasia market consists of revenues earned by entities by providing services such as telemedicine and remote monitoring, diagnostic testing services, hormone replacement therapy (HRT) services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital adrenal hyperplasia market also includes sales of glucocorticoids, mineralocorticoids, and adrenal androgens. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Adrenal Hyperplasia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congenital adrenal hyperplasia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congenital adrenal hyperplasia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital adrenal hyperplasia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Classic Congenital Adrenal Hyperplasia; Non-Classic Congenital Adrenal Hyperplasia
  • 2) By Treatment And Diagnosis: Diagnosis; Treatment
  • 3) By End-Use: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
  • Subsegments:
  • 1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia; Simple Virilizing Classic Congenital Adrenal Hyperplasia
  • 2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia; Mild Non-Classic Congenital Adrenal Hyperplasia
  • Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Congenital Adrenal Hyperplasia Market Characteristics

3. Congenital Adrenal Hyperplasia Market Trends And Strategies

4. Congenital Adrenal Hyperplasia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Congenital Adrenal Hyperplasia Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Congenital Adrenal Hyperplasia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Congenital Adrenal Hyperplasia Market Growth Rate Analysis
  • 5.4. Global Congenital Adrenal Hyperplasia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Congenital Adrenal Hyperplasia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Congenital Adrenal Hyperplasia Total Addressable Market (TAM)

6. Congenital Adrenal Hyperplasia Market Segmentation

  • 6.1. Global Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Classic Congenital Adrenal Hyperplasia
  • Non-Classic Congenital Adrenal Hyperplasia
  • 6.2. Global Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnosis
  • Treatment
  • 6.3. Global Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research Institutes
  • 6.4. Global Congenital Adrenal Hyperplasia Market, Sub-Segmentation Of Classic Congenital Adrenal Hyperplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Salt-Wasting Classic Congenital Adrenal Hyperplasia
  • Simple Virilizing Classic Congenital Adrenal Hyperplasia
  • 6.5. Global Congenital Adrenal Hyperplasia Market, Sub-Segmentation Of Non-Classic Congenital Adrenal Hyperplasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Late-Onset Non-Classic Congenital Adrenal Hyperplasia
  • Mild Non-Classic Congenital Adrenal Hyperplasia

7. Congenital Adrenal Hyperplasia Market Regional And Country Analysis

  • 7.1. Global Congenital Adrenal Hyperplasia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Congenital Adrenal Hyperplasia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Congenital Adrenal Hyperplasia Market

  • 8.1. Asia-Pacific Congenital Adrenal Hyperplasia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Congenital Adrenal Hyperplasia Market

  • 9.1. China Congenital Adrenal Hyperplasia Market Overview
  • 9.2. China Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Congenital Adrenal Hyperplasia Market

  • 10.1. India Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Congenital Adrenal Hyperplasia Market

  • 11.1. Japan Congenital Adrenal Hyperplasia Market Overview
  • 11.2. Japan Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Congenital Adrenal Hyperplasia Market

  • 12.1. Australia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Congenital Adrenal Hyperplasia Market

  • 13.1. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Congenital Adrenal Hyperplasia Market

  • 14.1. South Korea Congenital Adrenal Hyperplasia Market Overview
  • 14.2. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Congenital Adrenal Hyperplasia Market

  • 15.1. Western Europe Congenital Adrenal Hyperplasia Market Overview
  • 15.2. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Congenital Adrenal Hyperplasia Market

  • 16.1. UK Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Congenital Adrenal Hyperplasia Market

  • 17.1. Germany Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Congenital Adrenal Hyperplasia Market

  • 18.1. France Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Congenital Adrenal Hyperplasia Market

  • 19.1. Italy Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Congenital Adrenal Hyperplasia Market

  • 20.1. Spain Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Congenital Adrenal Hyperplasia Market

  • 21.1. Eastern Europe Congenital Adrenal Hyperplasia Market Overview
  • 21.2. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Congenital Adrenal Hyperplasia Market

  • 22.1. Russia Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Congenital Adrenal Hyperplasia Market

  • 23.1. North America Congenital Adrenal Hyperplasia Market Overview
  • 23.2. North America Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Congenital Adrenal Hyperplasia Market

  • 24.1. USA Congenital Adrenal Hyperplasia Market Overview
  • 24.2. USA Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Congenital Adrenal Hyperplasia Market

  • 25.1. Canada Congenital Adrenal Hyperplasia Market Overview
  • 25.2. Canada Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Congenital Adrenal Hyperplasia Market

  • 26.1. South America Congenital Adrenal Hyperplasia Market Overview
  • 26.2. South America Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Congenital Adrenal Hyperplasia Market

  • 27.1. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Congenital Adrenal Hyperplasia Market

  • 28.1. Middle East Congenital Adrenal Hyperplasia Market Overview
  • 28.2. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Congenital Adrenal Hyperplasia Market

  • 29.1. Africa Congenital Adrenal Hyperplasia Market Overview
  • 29.2. Africa Congenital Adrenal Hyperplasia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Congenital Adrenal Hyperplasia Market, Segmentation By Treatment And Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Congenital Adrenal Hyperplasia Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Congenital Adrenal Hyperplasia Market Competitive Landscape And Company Profiles

  • 30.1. Congenital Adrenal Hyperplasia Market Competitive Landscape
  • 30.2. Congenital Adrenal Hyperplasia Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Congenital Adrenal Hyperplasia Market Other Major And Innovative Companies

  • 31.1. Eton Pharmaceuticals Inc
  • 31.2. Teva Pharmaceutical Industries
  • 31.3. Macleods Pharmaceuticals
  • 31.4. H. Lundbeck A/S
  • 31.5. Neurocrine Biosciences Inc.
  • 31.6. BridgeBio Pharma Inc
  • 31.7. Regenxbio Inc.
  • 31.8. Millendo Therapeutics Inc.
  • 31.9. Applied Therapeutics, Inc.
  • 31.10. OMass Therapeutics Limited
  • 31.11. ViennaLab Diagnostics GmbH
  • 31.12. EffRx Pharmaceuticals SA
  • 31.13. Adrenas Therapeutics Inc
  • 31.14. HBM Alpha Therapeutics
  • 31.15. Spruce Biosciences Inc.

32. Global Congenital Adrenal Hyperplasia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congenital Adrenal Hyperplasia Market

34. Recent Developments In The Congenital Adrenal Hyperplasia Market

35. Congenital Adrenal Hyperplasia Market High Potential Countries, Segments and Strategies

  • 35.1 Congenital Adrenal Hyperplasia Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Congenital Adrenal Hyperplasia Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Congenital Adrenal Hyperplasia Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer